In the phase 3 PANOVA-3 trial, patients who underwent tumor-treating fields therapy had extended overall survival vs standard ...

但细胞焦亡释放的促炎细胞因子，如 IL-1β，也可能抑制抗肿瘤免疫反应，形成免疫抑制微环境。 紫杉醇：化疗药物的中流砥柱 紫杉醇（Paclitaxel）源自西部紫杉树皮，是广泛用于治疗多种癌症的化疗药物。它主要通过稳定微管蛋白，促进其聚合并抑制解聚 ...

特拉维夫 - 专注于肿瘤学和罕见疾病的生物制药公司BioLineRx Ltd. (NASDAQ:TASE: BLRX)，市值为1400万美元，在芝加哥举行的美国临床肿瘤学会 (ASCO)年会上公布了其CheMo4METPANC二期试验的新数据。根据 InvestingPro ...

Shares of BioLineRx (BLRX) skyrocketed 32% on Friday after the biopharmaceutical company announced positive data from the ...

Patients with progressive HER2-positive gastroesophageal (GE) cancer lived significantly longer when they received the ...

This study identifies 53BP1 as an interaction partner of GMCL1 (a likely CUL3 substrate receptor). The study seeks to link this finding to regulation of the mitotic surveillance pathway and paclitaxel ...

Meitheal Pharma launches generic paclitaxel formulation in US via exclusive commercial licensing agreement with Hong Kong King-Friend: Chicago Saturday, May 31, 2025, 14:00 Hrs [I ...

Paclitaxel is a prominent natural compound used for the treatment of refractory cancers. It was discovered as part of a National Cancer Institute program where extracts of thousands of plants were ...

BioLineRx shares were higher after the company reported favorable data from a pilot phase of a drug study of pancreatic cancer patients. Shares rose 45% to $5.51 Friday and are down about 36% this ...